Pegylated interferon fractal pharmacokinetics

Individualized dosing for hepatitis c virus infection

Mamta K. Jain, Jotam G. Pasipanodya, Lara Alder, William M. Lee, Tawanda Gumbo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite recent advances in hepatitis C virus (HCV) therapeutics, the combination of pegylated interferon and ribavirin (PEGIFN/RBV) remains the cornerstone of treatment. Optimization and individualization of PEGIFN dosing could improve outcomes. Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/ RBV were analyzed using multicompartmental pharmacokinetic models. For each patient, pharmacokinetic parameter estimates, weight, age, interleukin-28B (IL-28B) single-nucleotide polymorphism, CD4 count, baseline HCV RNA, gender, race, and HIV status were examined using classification and regression tree analysis to identify factors predictive of sustained viral response (SVR). Survival analysis was performed to compare the time to undetectable viral load in patients with and without the highest scoring predictor. PEGIFN concentrations varied at least 87-fold. Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag. Patient weight correlated with PEGIFN systemic clearance based on fractal geometry relationships. SVR was achieved in 36% of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of<0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of>93.7 kg. Patients with a PEGIFN AUC of>0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95% confidence interval, 1.21 to 2.04). PEGIFN exhibits wide pharmacokinetic variability, mainly driven by patient weight, so that the standard dose may not reach levels needed to achieve SVR. Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy.

Original languageEnglish (US)
Pages (from-to)1115-1120
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Hepatitis Viruses
Fractals
Virus Diseases
Interferons
Pharmacokinetics
Area Under Curve
Hepacivirus
Weights and Measures
Viral Load
Ribavirin
Interleukins
CD4 Lymphocyte Count
Survival Analysis
Single Nucleotide Polymorphism
Therapeutics
Genotype
Regression Analysis
HIV
RNA
Confidence Intervals

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Pegylated interferon fractal pharmacokinetics : Individualized dosing for hepatitis c virus infection. / Jain, Mamta K.; Pasipanodya, Jotam G.; Alder, Lara; Lee, William M.; Gumbo, Tawanda.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 3, 03.2013, p. 1115-1120.

Research output: Contribution to journalArticle

@article{c7d193fc18554ef9a035c990172375b1,
title = "Pegylated interferon fractal pharmacokinetics: Individualized dosing for hepatitis c virus infection",
abstract = "Despite recent advances in hepatitis C virus (HCV) therapeutics, the combination of pegylated interferon and ribavirin (PEGIFN/RBV) remains the cornerstone of treatment. Optimization and individualization of PEGIFN dosing could improve outcomes. Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/ RBV were analyzed using multicompartmental pharmacokinetic models. For each patient, pharmacokinetic parameter estimates, weight, age, interleukin-28B (IL-28B) single-nucleotide polymorphism, CD4 count, baseline HCV RNA, gender, race, and HIV status were examined using classification and regression tree analysis to identify factors predictive of sustained viral response (SVR). Survival analysis was performed to compare the time to undetectable viral load in patients with and without the highest scoring predictor. PEGIFN concentrations varied at least 87-fold. Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag. Patient weight correlated with PEGIFN systemic clearance based on fractal geometry relationships. SVR was achieved in 36{\%} of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of<0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of>93.7 kg. Patients with a PEGIFN AUC of>0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95{\%} confidence interval, 1.21 to 2.04). PEGIFN exhibits wide pharmacokinetic variability, mainly driven by patient weight, so that the standard dose may not reach levels needed to achieve SVR. Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy.",
author = "Jain, {Mamta K.} and Pasipanodya, {Jotam G.} and Lara Alder and Lee, {William M.} and Tawanda Gumbo",
year = "2013",
month = "3",
doi = "10.1128/AAC.02208-12",
language = "English (US)",
volume = "57",
pages = "1115--1120",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Pegylated interferon fractal pharmacokinetics

T2 - Individualized dosing for hepatitis c virus infection

AU - Jain, Mamta K.

AU - Pasipanodya, Jotam G.

AU - Alder, Lara

AU - Lee, William M.

AU - Gumbo, Tawanda

PY - 2013/3

Y1 - 2013/3

N2 - Despite recent advances in hepatitis C virus (HCV) therapeutics, the combination of pegylated interferon and ribavirin (PEGIFN/RBV) remains the cornerstone of treatment. Optimization and individualization of PEGIFN dosing could improve outcomes. Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/ RBV were analyzed using multicompartmental pharmacokinetic models. For each patient, pharmacokinetic parameter estimates, weight, age, interleukin-28B (IL-28B) single-nucleotide polymorphism, CD4 count, baseline HCV RNA, gender, race, and HIV status were examined using classification and regression tree analysis to identify factors predictive of sustained viral response (SVR). Survival analysis was performed to compare the time to undetectable viral load in patients with and without the highest scoring predictor. PEGIFN concentrations varied at least 87-fold. Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag. Patient weight correlated with PEGIFN systemic clearance based on fractal geometry relationships. SVR was achieved in 36% of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of<0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of>93.7 kg. Patients with a PEGIFN AUC of>0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95% confidence interval, 1.21 to 2.04). PEGIFN exhibits wide pharmacokinetic variability, mainly driven by patient weight, so that the standard dose may not reach levels needed to achieve SVR. Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy.

AB - Despite recent advances in hepatitis C virus (HCV) therapeutics, the combination of pegylated interferon and ribavirin (PEGIFN/RBV) remains the cornerstone of treatment. Optimization and individualization of PEGIFN dosing could improve outcomes. Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/ RBV were analyzed using multicompartmental pharmacokinetic models. For each patient, pharmacokinetic parameter estimates, weight, age, interleukin-28B (IL-28B) single-nucleotide polymorphism, CD4 count, baseline HCV RNA, gender, race, and HIV status were examined using classification and regression tree analysis to identify factors predictive of sustained viral response (SVR). Survival analysis was performed to compare the time to undetectable viral load in patients with and without the highest scoring predictor. PEGIFN concentrations varied at least 87-fold. Pharmacokinetics were best described by a two-compartment model with an 8.4-h absorption lag. Patient weight correlated with PEGIFN systemic clearance based on fractal geometry relationships. SVR was achieved in 36% of patients; a PEGIFN cumulative 1-week area under the curve (AUC) of<0.79 mg · h/liter scored highest in predicting poor response, followed by a weight of>93.7 kg. Patients with a PEGIFN AUC of>0.79 mg · h/liter achieved undetectable viral load more rapidly than those with a lower AUC (hazard ratio, 1.63; 95% confidence interval, 1.21 to 2.04). PEGIFN exhibits wide pharmacokinetic variability, mainly driven by patient weight, so that the standard dose may not reach levels needed to achieve SVR. Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy.

UR - http://www.scopus.com/inward/record.url?scp=84874078862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874078862&partnerID=8YFLogxK

U2 - 10.1128/AAC.02208-12

DO - 10.1128/AAC.02208-12

M3 - Article

VL - 57

SP - 1115

EP - 1120

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -